patients from the first evidence of PCa (surgery date, radiation therapy date, ADT initiation, or diagnosis) beginning January 1996 through the end of follow-up. Outcomes Five types of CVD events (incident or fatal) following GnRH agonists or
Search Results
Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk
Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian
Factors Affecting Genetic Consultation in Adolescent and Young Adult Patients With Sarcoma
Grace E. McKay, Anna L. Zakas, Fauzia Osman, and Amanda Parkes
Primary Outcomes Of the 87 AYA patients with sarcoma identified in our study, only 22% (n=19) had documentation of a discussion about genetics with an oncology provider. There was no statistically significant difference in genetic discussion
BPI24-019: Estimation of Impact of Care Gap on Patient Outcome and Health Care Cost Burden Using Real World Data in Early-Stage NSCLC—An Empirical Study for Delay in Surgery
Atharv Sharma, Manu Prasad, Tianyuan Hu, Arunav Saikia, Prabhakar Gaur, Venkata Sai Sumanth Pulluri, and Stuti Jha
average of $4,806.84±$1,264.81 higher total healthcare resource costs ( P <0.001). Conclusion: Delay in surgery did not significantly impact eNSCLC patient outcomes, but substantially affected healthcare resource utilization. Similar results were
HSR22-141: Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Without Actionable Genomic Alterations (AGAs) Previously Treated With Platinum-Based Chemotherapy and Immunotherapy
Jerome H Goldschmidt, Anupama Vasudevan, Michelle Silver, Jackie Kwong, and Elizabeth Marrett
1. Clinical Outcomes by Subsequent Treatment *Other sTx group not shown due to small sample size
HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018
Weijia Wang, Edward Li, Kim Campbell, and Ali McBride
Introduction: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy that can result in hospitalization, dose reductions or treatment delays and compromised clinical outcomes. National Comprehensive Cancer
Delivering on the Promise of Patient-Centered Care
Patricia A. Ganz
Despite our success in improving survival outcomes in patients with cancer, the words “you have cancer” are still terrifying. These 3 words immediately conjure up the threat of death and the physical and emotional suffering associated with cancer
HSR20-102: Quality Outcomes in Colon Cancer
Michelle Moskal and Neeharika S. Makani
NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care
Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian, and Benjamin O. Anderson
mature and organized health care infrastructure. They make no recommendations about how resource expenditures should be prioritized to achieve the greatest clinical benefit and outcome. Most of the currently available clinical practice guidelines, such as
A Systematic Review of Clinical Decision Support Systems for Clinical Oncology Practice
Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen, and Barbara A. Olson-Bullis
-based standardization of cancer care, improving care delivery and patient outcomes. CDS tools have been incorporated across the patient care spectrum, encompassing prevention, diagnosis, and clinical monitoring. Common roles for CDS include computerized physician order
HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)
Kirsten Stuber, Habte A. Yimer, Karin Choquette, Sudhir Manda, Jennifer Clayton, Saulius Girnius, Joshua Richter, Presley Whidden, Kimberly Bogard, Dasha Cherepanov, and Stephen J. Noga
(QoL) and improving outcomes. We evaluated the feasibility of digital actigraphy (monitoring activity/rest) and electronic PRO (ePRO) data collection using wearable and mobile devices in an older MM pt population (median age 73 years). Methods
